Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9290778 | 0.84 | CYP19A1 (0.45) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9298473 | 0.83 | TRPA1 (0.37) | KDM4EGAAALDH1A1 | |
| SCHEMBL8965119 | 0.83 | TRPA1 (0.37) | KDM4EGAAALDH1A1 | |
| SCHEMBL7825330 | 0.83 | TRPA1 (0.37) | KDM4EGAAALDH1A1 | |
| SCHEMBL6283862 | 0.80 | CFTR (0.41) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7808015 | 0.76 | CFTR (0.40) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6597829 | 0.74 | CCR1 (0.39) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23354817 | 0.73 | CFTR (0.38) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9537727 | 0.73 | ALOX5 (0.33) | — | |
| SCHEMBL9297323 | 0.73 | ALDH1A1 (0.43) | SMN1; SMN2KDM4EGAAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881736-B1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-19 | — | — | US | disclosed |
| US-20050080277-A1 | Process for preparing optically active 2-[6-(hydroxy-methyl)-1,3-dioxan-4-yl] acetic acid derivatives | KANEKA CORPORATION (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1218005-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1288213-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2- 6-(HYDROXY-METHYL)-1,3-DIOXAN-4-YL]ACETIC ACID DERIVATIVES | KANEKA CORPORATION (JP) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080277-A1 | Process for preparing optically active 2-[6-(hydroxy-methyl)-1,3-dioxan-4-yl] acetic acid derivatives | HAAO, APEH, HPD | CYP19A1 121/4885CFTR 4695/4885SLC6A2 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.